| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Scott Department of Urology [G. Y., A. F., T. C. T.], Department of Pathology [G. A., T. M. W.], Verna and Marrs McLean Department of Biochemistry and Molecular Biology [J. W. H.], Baylor College of Medicine, Houston, Texas 77030, and Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland [A. D. M.]
The F-box protein Skp2 (Fbl1) is a positive regulator of G1-S transition and promotes ubiquitin-mediated proteolysis of the cyclin-dependent kinase inhibitor p27. Its overexpression has been implicated in cell transformation and oncogenesis in both in vitro and in vivo models. In this study, we investigated its role in human prostate cancer progression. Immunohistochemical analysis was performed on formalin-fixed paraffin sections of 622 radical prostatectomy specimens, 74 prostatic intraepithelial neoplasm specimens, as well as in 4 normal prostate organ donors assembled into tissue microarrays. We found that both luminal and basal epithelial cells in normal prostate had very low Skp2 levels, but Skp2 levels and labeling frequency increased dramatically in both premalignant lesions of prostatic intraepithelial neoplasm (P = 0.0252) and in prostate cancer (P = 0.0037). The Skp2 labeling frequency in cancer was positively correlated with preoperative serum prostate-specific antigen level (P = 0.0499) and Gleason score (P = 0.0002), whereas the Skp2 index was positively correlated with extraprostatic extension (P = 0.0454), clinical stage (P = 0.0170), as well as Gleason score (P = 0.0002). Kaplan-Meier analysis revealed that a higher Skp2 labeling index (>10) was a significant predictor of shorter biochemical recurrence-free survival time after radical prostatectomy (P < 0.0363, log-rank test). An inverse correlation of Skp2 was observed with both its biochemical target p27 expression in prostate cancer (P = 0.0003) and with its putative negative regulator, the PTEN tumor suppressor protein (P = 0.0444). These data suggest that induction of Skp2 may be causally linked with decreased levels of p27 in prostate cancer and implicate PTEN in the regulation of Skp2 expression in vivo, as previous tissue culture experiments have suggested.
This article has been cited by other articles:
|
|
 |
|
  H.-C. Huang, T.-D. Way, C.-L. Lin, and J.-K. Lin EGCG Stabilizes p27kip1 in E2-Stimulated MCF-7 Cells through Down-Regulation of the Skp2 Protein Endocrinology, December 1, 2008; 149(12): 5972 - 5983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Agarwal, T. G. P. Bumm, A. S. Corbin, T. O'Hare, M. Loriaux, J. VanDyke, S. G. Willis, J. Deininger, K. I. Nakayama, B. J. Druker, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease Blood, September 1, 2008; 112(5): 1960 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, D. Sun, P. Ji, J. Mohler, and L. Zhu An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells J. Cell Sci., August 1, 2008; 121(15): 2578 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Uddin, M. Ahmed, P. Bavi, R. El-Sayed, N. Al-Sanea, A. AbdulJabbar, L. H. Ashari, S. Alhomoud, F. Al-Dayel, A. R. Hussain, et al. Bortezomib (Velcade) Induces p27Kip1 Expression through S-Phase Kinase Protein 2 Degradation in Colorectal Cancer Cancer Res., May 1, 2008; 68(9): 3379 - 3388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Egozi, M. Shapira, G. Paor, O. Ben-Izhak, K. Skorecki, and D. D. Hershko Regulation of the cell cycle inhibitor p27 and its ubiquitin ligase Skp2 in differentiation of human embryonic stem cells FASEB J, September 1, 2007; 21(11): 2807 - 2817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Chang, F.-R. Chang, Y.-C. Wang, M.-R. Pan, W.-C. Hung, and Y.-C. Wu A bioactive withanolide Tubocapsanolide A inhibits proliferation of human lung cancer cells via repressing Skp2 expression Mol. Cancer Ther., May 1, 2007; 6(5): 1572 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ji, L. Goldin, H. Ren, D. Sun, D. Guardavaccaro, M. Pagano, and L. Zhu Skp2 Contains a Novel Cyclin A Binding Domain That Directly Protects Cyclin A from Inhibition by p27Kip1 J. Biol. Chem., August 18, 2006; 281(33): 24058 - 24069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Moro, A. A. Arbini, E. Marra, and M. Greco Up-regulation of Skp2 after Prostate Cancer Cell Adhesion to Basement Membranes Results in BRCA2 Degradation and Cell Proliferation J. Biol. Chem., August 4, 2006; 281(31): 22100 - 22107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res., March 1, 2006; 66(5): 2815 - 2825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Huang, H.-Y. Kang, C.-F. Li, H.-L. Eng, S.-C. Chou, C.-N. Lin, and C.-Y. Hsiung Skp2 Overexpression Is Highly Representative of Intrinsic Biological Aggressiveness and Independently Associated with Poor Prognosis in Primary Localized Myxofibrosarcomas Clin. Cancer Res., January 15, 2006; 12(2): 487 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Huang, K. M. Regan, F. Wang, D. Wang, D. I Smith, J. M. A. van Deursen, and D. J. Tindall Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation PNAS, February 1, 2005; 102(5): 1649 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, D. Ungermannova, L. Chen, and X. Liu Molecular and Biochemical Characterization of the Skp2-Cks1 Binding Interface J. Biol. Chem., December 3, 2004; 279(49): 51362 - 51369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Osoegawa, I. Yoshino, S. Tanaka, K. Sugio, T. Kameyama, M. Yamaguchi, and Y. Maehara Regulation of p27 by S-Phase Kinase-Associated Protein 2 Is Associated With Aggressiveness in Non-Small-Cell Lung Cancer J. Clin. Oncol., October 15, 2004; 22(20): 4165 - 4173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Liang, Y.-Y. Liang, K. Wrighton, D. Ungermannova, X.-P. Wang, F. C. Brunicardi, X. Liu, X.-H. Feng, and X. Lin Ubiquitination and Proteolysis of Cancer-Derived Smad4 Mutants by SCFSkp2 Mol. Cell. Biol., September 1, 2004; 24(17): 7524 - 7537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Min, J.-W. Cheong, J. Y. Kim, J. I. Eom, S. T. Lee, J. S. Hahn, Y. W. Ko, and M. H. Lee Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia Cancer Res., August 1, 2004; 64(15): 5225 - 5231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Min, J.-W. Cheong, M. H. Lee, J. Y. Kim, S. T. Lee, J. S. Hahn, and Y. W. Ko Elevated S-Phase Kinase-Associated Protein 2 Protein Expression in Acute Myelogenous Leukemia: Its Association with Constitutive Phosphorylation of Phosphatase and Tensin Homologue Protein and Poor Prognosis Clin. Cancer Res., August 1, 2004; 10(15): 5123 - 5130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Knowles, F. Axelrod, C. D. Browne, and J. W. Smith A Fatty Acid Synthase Blockade Induces Tumor Cell-cycle Arrest by Down-regulating Skp2 J. Biol. Chem., July 16, 2004; 279(29): 30540 - 30545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yokoi, K. Yasui, M. Mori, T. Iizasa, T. Fujisawa, and J. Inazawa Amplification and Overexpression of SKP2 Are Associated with Metastasis of Non-Small-Cell Lung Cancers to Lymph Nodes Am. J. Pathol., July 1, 2004; 165(1): 175 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-l. Chang, S. L Zheng, S. D. Isaacs, K. E. Wiley, A. Turner, G. Li, P. C. Walsh, D. A. Meyers, W. B. Isaacs, and J. Xu A Polymorphism in the CDKN1B Gene Is Associated with Increased Risk of Hereditary Prostate Cancer Cancer Res., March 15, 2004; 64(6): 1997 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Q. Zhu, F. H. Blackhall, M. Pintilie, P. Iyengar, N. Liu, J. Ho, T. Chomiak, D. Lau, T. Winton, F. A. Shepherd, et al. Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker Clin. Cancer Res., March 15, 2004; 10(6): 1984 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Yang and K. L. Burnstein Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm J. Biol. Chem., November 21, 2003; 278(47): 46862 - 46868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. V. Litvinov, A. M. De Marzo, and J. T. Isaacs Is the Achilles' Heel for Prostate Cancer Therapy a Gain of Function in Androgen Receptor Signaling? J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 2972 - 2982. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
